|
|||||
|
|
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS |
|
| Authors: | Park S Sapena R Kelaidi C Vassilieff D Bordessoule D Stamatoullas A Cheze S Beyne-Rauzy O Vey N Rose C Guerci A Natarajan-Amé Shanti Tertian Gérard Slama B Fenaux P Dreyfus F |
| Affiliation: | a Hôpital Cochin Assistance Publique des Hôpitaux de Paris (AP-HP), Paris V, France b Hôpital Avicenne, APHP, Bobigny, Paris XIII, France c CHU Dupuytren, Limoge, France d CHU de Rouen - Centre Henri Becquerel, Rouen, France e CHU Clémenceau, Caen, France f Hôpital Purpan, Toulouse, France g IPC Marseille, Marseille, France h Hôpital St Vincent de Paul, Lille, France i Hôpitaux de Brabois, Vandoeuvre Les Nancy, Nancy, France j Hôpital Hautepierre, Strasbourg, France k Hôpital Bicêtre, Le Kremlin Bicêtre, France l CHU d’Avignon, Avignon, France |
| Abstract: | We evaluated the prognostic value of serum ferritin (SF) level at diagnosis in 318 newly diagnosed IPSS low and int 1 (lower) risk MDS patients included in the French MDS registry, who did not require RBC transfusions and had baseline SF level determination. Increased baseline SF level (>300 ng/ml) was correlated with male gender, more pronounced anaemia, and diagnosis of RARS but had no negative impact on progression to AML or survival. |
| Keywords: | SF, serum ferritin Hb, hemoglobin MCV, mean corpsucular volume RBC, red blood cell ANC, absolute neutrophil count MDS, myelodysplastic syndrome |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |